Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.66 |
| ▸ | CTSL | P07711 | 8/20 | 0.63 |
| ▸ | CTSB | P07858 | 7/20 | 0.63 |
| ▸ | CTSK | P43235 | 5/20 | 0.63 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.61 |
| ▸ | CTSS | P25774 | 3/20 | 0.59 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.59 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.59 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14513399 | 1.00 | CAPN1 (0.66) | CAPN1CTSLCTSBCTSKHTRA1 | |
| SCHEMBL29372797 | 1.00 | CAPN1 (0.66) | CAPN1CTSLCTSBCTSKHTRA1 | |
| Water SCHEMBL29578866 | 0.99 | CAPN1 (0.65) | CAPN1CTSLCTSBCTSKHTRA1 | |
| SCHEMBL29358994 | 0.92 | CAPN1 (0.64) | CAPN1CTSLCTSBCTSKHTRA1 | |
| SCHEMBL29577384 | 0.89 | CAPN1 (0.70) | CAPN1CTSLCTSBCTSKHTRA1 | |
| SCHEMBL21219280 | 0.89 | CAPN1 (0.74) | CAPN1CTSLCTSBCTSKHTRA1 | |
| SCHEMBL21219352 | 0.89 | CAPN1 (0.74) | CAPN1CTSLCTSBCTSKHTRA1 | |
| SCHEMBL21219351 | 0.89 | CAPN1 (0.74) | CAPN1CTSLCTSBCTSKHTRA1 | |
| SCHEMBL9831181 | 0.89 | CAPN1 (0.74) | CAPN1CTSLCTSBCTSKHTRA1 | |
| SCHEMBL29483597 | 0.89 | CAPN1 (0.74) | CAPN1CTSLCTSBCTSKHTRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12350260-B2 | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning | UNIVERSITE DE BRETAGNE OCCIDENTALE (FR) | 2025-07-08 | — | — | US | claimed |
| US-20220193048-A1 | PROTEASE-ACTIVATED RECEPTOR-2 INHIBITORS FOR THE TREATMENT OF SENSORY NEUROPATHY INDUCED BY A MARINE NEUROTOXIC POISONING | UNIVERSITE DE BRETAGNE OCCIDENTALE (FR) | 2022-06-23 | — | — | US | claimed |
| WO-2022072504-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| EP-3946332-A1 | PROTEASE-ACTIVATED RECEPTOR-2 INHIBITORS FOR THE TREATMENT OF SENSORY NEUROPATHY INDUCED BY A MARINE NEUROTOXIC POISONING | Université de Bretagne Occidentale (FR) | 2022-02-09 | — | — | EP | claimed |
| US-12350260-B2 | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning | UNIVERSITE DE BRETAGNE OCCIDENTALE (FR) | 2025-07-08 | — | — | US | disclosed |
| EP-4208174-A2 | NUCLEIC ACID-DERIVATIZED THERAPEUTICS | The University of Chicago (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20220193048-A1 | PROTEASE-ACTIVATED RECEPTOR-2 INHIBITORS FOR THE TREATMENT OF SENSORY NEUROPATHY INDUCED BY A MARINE NEUROTOXIC POISONING | UNIVERSITE DE BRETAGNE OCCIDENTALE (FR) | 2022-06-23 | — | — | US | disclosed |
| US-20220193048-A1 | PROTEASE-ACTIVATED RECEPTOR-2 INHIBITORS FOR THE TREATMENT OF SENSORY NEUROPATHY INDUCED BY A MARINE NEUROTOXIC POISONING | UNIVERSITE DE BRETAGNE OCCIDENTALE (FR) | 2022-06-23 | — | — | US | disclosed |
| EP-3946332-A1 | PROTEASE-ACTIVATED RECEPTOR-2 INHIBITORS FOR THE TREATMENT OF SENSORY NEUROPATHY INDUCED BY A MARINE NEUROTOXIC POISONING | Université de Bretagne Occidentale (FR) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193048-A1 | PROTEASE-ACTIVATED RECEPTOR-2 INHIBITORS FOR THE TREATMENT OF SENSORY NEUROPATHY INDUCED BY A MARINE NEUROTOXIC POISONING | PRSS12, TPSB2, F2RL1 | CAPN1 351/4885CTSL 123/4885CTSB 80/4885 |
| US-12350260-B2 | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning | PRSS12, TPSB2, F2RL1 | CAPN1 351/4885CTSL 123/4885CTSB 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.